Merck (MRK) Stock Price, Fundamentals & Analysis

What MRK does

Merck (MRK) is a stock listed on the Xetra market in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. The company operates as a science and technology group with a presence in Europe, North America, Latin America, the Middle East and Africa, and the Asia Pacific. Its Life Science segment supplies products, solutions, and services to academic and research labs, biotech and pharmaceutical companies, and the industrial sector, including reagents, consumables, instruments, software, and services for research, production, and testing. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals in areas such as oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders.

Key numbers explained

• The current price of 135 EUR reflects the latest trading value of one share of Merck on Xetra.
• The trailing P/E ratio of 24.8 shows how much investors pay per euro of the company's last 12 months of earnings; a higher number can indicate higher growth expectations.
• The forward P/E ratio of 15.1 is based on expected future earnings and is often used to compare valuation across companies.
• The dividend yield of 1.63% indicates the annual dividend payment as a percentage of the current share price.
• The ex-dividend date of Apr 27, 2026 is the cutoff date; buyers on or after this date are not eligible for the next dividend payment.
• The beta of 0.81 suggests the stock has historically been less volatile than the overall market.
• The 52-week price range of 100.7 – 148.8 shows the lowest and highest traded prices over the past year.
• The price-to-book ratio of 1.94 compares the market price to the company's book value per share.

What to watch

Investors tracking Merck may watch its upcoming earnings release on Nov 12, 2026 for updates on revenue and profit trends. The revenue growth of 3.4% year over year and the profit margin of 11.2% offer a sense of the company's top-line expansion and cost control. The debt-to-equity ratio of 40.6% provides a view of how much the company relies on debt relative to shareholder equity. As a Healthcare stock, MRK can be influenced by regulatory decisions, patent timelines, and R&D outcomes. It is part of the DAX, so broader index movements may affect its price.